[go: up one dir, main page]

DE60335755D1 - Pharmazeutische Zusammensetzungen, die immunologisch aktive Herpes simplex Virus Proteinfragmente enthalten - Google Patents

Pharmazeutische Zusammensetzungen, die immunologisch aktive Herpes simplex Virus Proteinfragmente enthalten

Info

Publication number
DE60335755D1
DE60335755D1 DE60335755T DE60335755T DE60335755D1 DE 60335755 D1 DE60335755 D1 DE 60335755D1 DE 60335755 T DE60335755 T DE 60335755T DE 60335755 T DE60335755 T DE 60335755T DE 60335755 D1 DE60335755 D1 DE 60335755D1
Authority
DE
Germany
Prior art keywords
antigens
hsv
compositions containing
immunologically active
pharmaceutical compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60335755T
Other languages
English (en)
Inventor
David M Koelle
Zhi Liu
Lawrence Corey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Original Assignee
University of Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington filed Critical University of Washington
Application granted granted Critical
Publication of DE60335755D1 publication Critical patent/DE60335755D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
DE60335755T 2002-07-18 2003-07-18 Pharmazeutische Zusammensetzungen, die immunologisch aktive Herpes simplex Virus Proteinfragmente enthalten Expired - Lifetime DE60335755D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39679102P 2002-07-18 2002-07-18

Publications (1)

Publication Number Publication Date
DE60335755D1 true DE60335755D1 (de) 2011-02-24

Family

ID=30770951

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60324678T Expired - Lifetime DE60324678D1 (de) 2002-07-18 2003-07-18 N t-lymphozyten und damit identifizierte hsv-antigene
DE60335755T Expired - Lifetime DE60335755D1 (de) 2002-07-18 2003-07-18 Pharmazeutische Zusammensetzungen, die immunologisch aktive Herpes simplex Virus Proteinfragmente enthalten

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE60324678T Expired - Lifetime DE60324678D1 (de) 2002-07-18 2003-07-18 N t-lymphozyten und damit identifizierte hsv-antigene

Country Status (8)

Country Link
US (7) US7078041B2 (de)
EP (5) EP1523582B1 (de)
AT (2) ATE494907T1 (de)
AU (1) AU2003252052A1 (de)
CA (1) CA2492598C (de)
DE (2) DE60324678D1 (de)
DK (2) DK2011510T3 (de)
WO (1) WO2004009021A2 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010085348A (ko) * 1998-08-07 2001-09-07 추후보정 면역능을 갖는 헤르페스 심플렉스 바이러스 항원 및 이를이용하는 방법
RU2416797C2 (ru) * 2005-09-08 2011-04-20 Мологен Аг ФУНКЦИОНАЛЬНЫЙ ИММУНОАНАЛИЗ in vitro
US20070122415A1 (en) * 2005-11-29 2007-05-31 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compound and method for suppressing retroviral replication
CA2658484A1 (en) 2006-07-20 2008-01-24 Vical Incorporated Compositions and methods for vaccinating against hsv-2
US8460674B2 (en) 2009-02-07 2013-06-11 University Of Washington HSV-1 epitopes and methods for using same
EP2413950A4 (de) 2009-04-03 2013-05-01 Univ Washington Antigenes hsv-2-peptid und verwendungsverfahren dafür
NZ597182A (en) * 2009-05-22 2014-07-25 Genocea Biosciences Inc Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
JP6055776B2 (ja) 2010-11-24 2016-12-27 ジェノセア バイオサイエンシーズ， インコーポレイテッド 単純ヘルペスウイルス２型に対するワクチン：免疫応答を誘発する組成物及び方法
WO2013078299A1 (en) 2011-11-23 2013-05-30 Genocea Biosciences, Inc. Nucleic acid vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
US9938498B2 (en) 2012-05-07 2018-04-10 Nkmax Co., Ltd. Method for the induction and expansion of natural killer cells derived from peripheral blood mononuclear cells
WO2013168978A1 (ko) * 2012-05-07 2013-11-14 고려대학교 산학협력단 말초혈액단핵구 유래 자연 살해세포의 유도 및 증식 방법
ES2673556T3 (es) 2012-05-16 2018-06-22 Immune Design Corp. Vacunas para el VHS-2
CN104694553B (zh) * 2013-12-05 2018-04-17 长春百克生物科技股份公司 生殖器疱疹疫苗
WO2017075141A1 (en) * 2015-10-27 2017-05-04 Arizona Board Of Regents On Behalf Of Arizona State University High throughput identification of t-cell recognition antigens and epitopes
EP3519427A4 (de) 2016-09-28 2020-03-11 Genocea Biosciences Inc. Verfahren und zusammensetzungen zur behandlung von herpes
US20200164060A1 (en) * 2017-07-21 2020-05-28 Fred Hutchinson Cancer Research Center Herpes simplex virus vaccine epitopes specifically recognized by tissue resident memory t cells
CA3089853A1 (en) 2018-02-01 2019-08-08 Nkmax Co., Ltd. Method of producing natural killer cells and composition for treating cancer
WO2020027102A1 (ja) 2018-08-01 2020-02-06 イーグル工業株式会社 摺動部品
CN112424514B (zh) 2018-08-24 2023-04-28 伊格尔工业股份有限公司 滑动部件
KR102661123B1 (ko) 2018-10-24 2024-04-29 이구루코교 가부시기가이샤 슬라이딩 부재
WO2020110922A1 (ja) 2018-11-30 2020-06-04 イーグル工業株式会社 摺動部品
US11821521B2 (en) 2018-12-21 2023-11-21 Eagle Industry Co., Ltd. Sliding component
EP3922871B1 (de) 2019-02-04 2024-01-24 Eagle Industry Co., Ltd. Gleitkomponente
CN117432709A (zh) 2019-02-14 2024-01-23 伊格尔工业股份有限公司 滑动部件
CN113454353B (zh) 2019-02-21 2023-05-02 伊格尔工业股份有限公司 滑动部件
EP4006368B1 (de) 2019-07-26 2024-10-09 Eagle Industry Co., Ltd. Gleitkomponente
KR20230008819A (ko) 2020-06-02 2023-01-16 이구루코교 가부시기가이샤 슬라이딩 부품
EP4160058A4 (de) 2020-06-02 2024-07-03 Eagle Industry Co., Ltd. Schiebekomponente
EP4372253A4 (de) * 2021-07-13 2025-07-16 Eagle Ind Co Ltd Schiebekomponenten

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4429008B1 (en) 1981-12-10 1995-05-16 Univ California Thiol reactive liposomes
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4762708A (en) * 1982-02-18 1988-08-09 University Patents, Inc. Materials and methods for herpes simplex virus vaccination
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
JPS59116229A (ja) 1982-12-24 1984-07-05 Teijin Ltd 細胞毒性複合体を活性成分とする癌治療用剤およびその製造法
US7264817B1 (en) * 1983-08-30 2007-09-04 Genentech, Inc. Immunogenic composition based on a truncated derivative of a membrane bound protein and process for making it
US4873088A (en) 1983-09-06 1989-10-10 Liposome Technology, Inc. Liposome drug delivery method and composition
US5171568A (en) * 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
US4618578A (en) * 1984-07-17 1986-10-21 Chiron Corporation Expression of glycoprotein D of herpes simplex virus
US4859587A (en) * 1984-06-04 1989-08-22 Institut Merieux Recombinant herpes simplex viruses, vaccines and methods
US5612041A (en) * 1984-07-17 1997-03-18 Chiron Corporation Recombinant herpes simplex gD vaccine
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5538724A (en) * 1987-08-11 1996-07-23 The Board Of Trustees For The Leland Stanford Junior Univ. Method of control leukocyte extravasation
WO1989001973A2 (en) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
EP0487587A1 (de) 1989-08-18 1992-06-03 Chiron Corporation Rekombinante retroviren um vektorkonstruktionen an zielzellen zu liefern
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
TW232710B (de) * 1991-09-13 1994-10-21 American Cyanamid Co
DE69327599T2 (de) 1992-06-25 2000-08-10 Smithkline Beecham Biolog Adjuvantien enthaltende Impfstoffzusammensetzung
CN1133594A (zh) * 1993-08-20 1996-10-16 史密丝克莱恩比彻姆公司 单纯性疱疹病毒-2ul26基因，衣壳蛋白，免疫测定和蛋白酶抑制剂
US5426039A (en) 1993-09-08 1995-06-20 Bio-Rad Laboratories, Inc. Direct molecular cloning of primer extended DNA containing an alkane diol
GB9325496D0 (en) * 1993-12-14 1994-02-16 Smithkline Beecham Biolog Vaccines
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
EP0737205A1 (de) * 1993-12-28 1996-10-16 Chiron Mimotopes Pty. Ltd. T-zell epitope
ATE420171T1 (de) 1994-07-15 2009-01-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
EP0871747A1 (de) 1996-01-02 1998-10-21 Chiron Viagene, Inc. Immunstimulierung vermittelt durch genmodifizierte dendritische zellen
US5741492A (en) * 1996-01-23 1998-04-21 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
BR9712366A (pt) * 1996-10-23 1999-08-31 American Home Prod Gene de gd2 do vírus do herpes simples hsv2 isolado, plasmídeo compreendendo o mesmo, e, processos de induzir, em indivíduo, uma resposta imune contra hsv2 gd2, de tratar um indíviduo que está infectado com hsv, e, de prevenir que um indivíduo fique infectado com hsv
WO1998020016A1 (en) * 1996-11-04 1998-05-14 Smithkline Beecham Corporation Novel coding sequences from herpes simplex virus type-2
KR20010085348A (ko) 1998-08-07 2001-09-07 추후보정 면역능을 갖는 헤르페스 심플렉스 바이러스 항원 및 이를이용하는 방법
US6692752B1 (en) * 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
EP1222281B1 (de) 1999-09-30 2006-11-15 University of Washington Immunologisch relevante antigene aus herpes simplexvirus
US6375652B1 (en) * 2000-05-04 2002-04-23 Brymill Corporation Cutaneous cryosurgical clamp
EP1297147B8 (de) * 2000-06-29 2007-02-21 Corixa Corporation Zusammensetzung zur diagnose und behandlung von herpes simplex virusinfektionen
US6821519B2 (en) * 2000-06-29 2004-11-23 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
US20030027322A1 (en) * 2000-11-29 2003-02-06 Federoff Howard J. Helper virus-free herpesvirus amplicon particles and uses thereof
US8092791B2 (en) * 2001-05-23 2012-01-10 University Of Rochester Method of producing herpes simplex virus amplicons, resulting amplicons, and their use
CA2454750C (en) * 2001-07-31 2012-09-18 David M. Koelle Immunologically significant herpes simplex virus antigens and methods for using same
US20030219448A1 (en) * 2002-05-24 2003-11-27 Cedars-Sinai Medical Center Peptide epitope-based vaccine for treating herpes simplex virus infections and related diseases

Also Published As

Publication number Publication date
US8197824B2 (en) 2012-06-12
US20130189294A1 (en) 2013-07-25
US20160095918A1 (en) 2016-04-07
AU2003252052A8 (en) 2004-02-09
DK1523582T3 (da) 2009-03-02
US20130011425A1 (en) 2013-01-10
CA2492598C (en) 2013-12-17
EP2316479B8 (de) 2015-03-18
US9138473B2 (en) 2015-09-22
DE60324678D1 (de) 2008-12-24
EP2316479B1 (de) 2014-12-03
EP1523582B1 (de) 2008-11-12
EP2316479A3 (de) 2011-07-06
US7078041B2 (en) 2006-07-18
EP2011510A2 (de) 2009-01-07
US9675688B2 (en) 2017-06-13
EP2865386B1 (de) 2017-07-05
EP1523582A2 (de) 2005-04-20
EP2316479A2 (de) 2011-05-04
US20040072152A1 (en) 2004-04-15
ATE494907T1 (de) 2011-01-15
EP2263686B1 (de) 2012-12-26
DK2011510T3 (da) 2011-03-28
AU2003252052A1 (en) 2004-02-09
US20090148468A1 (en) 2009-06-11
WO2004009021A3 (en) 2004-06-03
CA2492598A1 (en) 2004-01-29
EP2865386A1 (de) 2015-04-29
EP2011510B1 (de) 2011-01-12
WO2004009021A2 (en) 2004-01-29
EP2263686A1 (de) 2010-12-22
EP2011510A3 (de) 2009-04-08
ATE414176T1 (de) 2008-11-15
EP1523582A4 (de) 2007-02-07
US7666434B2 (en) 2010-02-23
US20110135687A1 (en) 2011-06-09
US7431934B2 (en) 2008-10-07
US20060216304A1 (en) 2006-09-28

Similar Documents

Publication Publication Date Title
DE60335755D1 (de) Pharmazeutische Zusammensetzungen, die immunologisch aktive Herpes simplex Virus Proteinfragmente enthalten
NO20021479D0 (no) Immunologiske signifikante herpes simplex virus antigener og metoder for å identifisere og å bruke dem
Joshi et al. Visceral leishmaniasis: advancements in vaccine development via classical and molecular approaches
AR020134A1 (es) Antigenos inmunologicos contra el virus herpes simplex y metodos para el uso de los mismos
WO2003011893A3 (en) Immunologically significant herpes simplex virus antigens and methods for using same
WO2001082963A3 (en) Method of identifying and producing antigen peptides and use thereof as vaccines
RU2324493C2 (ru) Способ применения композиций, содержащих белки теплового шока или альфа-2-макроглобулин, для лечения рака и инфекционных болезней
CY1106152T1 (el) Νεα ανοσογονα αντι-hiv (ανατοξινες), μεθοδοι παρασκευης και εφαρμογη στην προληψη και στην αγωγη του aids
BR9912653A (pt) Vìrus de herpes atenuado, cepa de vìrus, célula dendrìtica, processo para produzir um célula, composição farmacêutica, uso de um vìrus, e, processo para executar a terapia de gene em um paciente humano ou animal ou para tratar ou prevenir uma infecção patogênica ou câncer para tratar paciente animal
WO2005116270A3 (en) Influenza virus vaccine composition and method of use
EP4226938A3 (de) Coronavirus-impfstoff
WO2023147092A3 (en) Coronavirus vaccine
EP1471936A4 (de) Hiv-vakzine und anwendungsverfahren
MX2023012368A (es) Vacuna de virus.
AR005750A1 (es) Composicion farmaceutica para tratar o prevenir infecciones con zoster en personas infectadas con el virus de varicela zoster y procedimiento para preparar dicha composicion
Carneiro et al. Vaccination with L. infantum chagasi nucleosomal histones confers protection against new world cutaneous leishmaniasis caused by Leishmania braziliensis
YU99603A (sh) Geni koji su povezani sa virulencijom parazita laišmanije
WO2003057823A3 (en) Epitope synchronization in antigen presenting cells
Haddad et al. Review of development of live vaccines against leishmaniasis
AU4300700A (en) Inactivated cytokines for immunisation
Kumar et al. Role of Vaccines on Human Health-A Review
Papadopoulou et al. Recent progress in vaccine development against Leishmania species infections
Slater Human malaria parasites
Thomson IMMUNOLOGICAL AND PROTECTIVE RESPONSES TO A HERPES SIMPLEX VIRUS SUBUNIT VACCINE IN A LABIAL INFECTION MODEL IN MICE.
RU98117675A (ru) Лекарственный состав с иммуномодуляторным действием, содержащий пептиды и вспомогательные средства